References Part 2

Hosseini-Moghaddam SM, Krishnan RJ, Guo H, Kumar D. Cytomegalovirus infection and graft rejection as risk factors for pneumocystis pneumonia in solid organ transplant recipients: A systematic review and meta-analysis. Clin Transplant. 2018;32(8):e13339.

Hu Z, Wang W, Li Z, Ye S, Zheng SS. Recipient outcomes of salvage liver transplantation versus primary liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012;18:1316–23.

Huh KH, Lee JG, Ha J, Oh CK, Ju MK Kim CD, et al. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial. Nephrol Dial Transplant. 2017;32(8):1415–24.

Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol. 2008;52:587–98.

Ifudu O, Paul HR, Homel P, Friedman EA. Predictive value of functional status for mortality in patients on maintenance hemodialysis. Am J Nephrol. 1998;18:109–16.

ISHLT Monograph Series. Volume 2: Pediatric Heart Transplantation. Canter CE, Kirklin JK (eds). April 2008. Available from: https://www.ishlt.org/publications-resources/monograph-series/monograph-volume-2 (accessed June 2017).

ISHLT Monograph Series. Volume 6: ISHLT Guidelines for the Care of Heart Transplant Recipients. Costanzo MR, Hunt SA, Taylor DO, Kirklin JK (eds). April 2012. Available from: https://www.ishlt.org/publications-resources/monograph-series/monograph-volume-6 (accessed June 2017).

ISHLT Monograph Series. Volume 7: Pediatric Lung Transplantation. Goldfarb S, Benden C, Sweet S, Kirklin JK (eds). April 2013. Available from: https://www.ishlt.org/publications-resources/monograph-series/monograph-volume-7 (accessed June 2017).

Iwasaki K, Kitahata N, Miwa Y, Uchida K, Matsuoka Y, Horimi K, et al. Suppressive effect of everolimus on IL-2, IL-10, IL-21, and IFNγ Levels: implications for the successful minimization of Calcineurin Inhibitor Use in Transplantation. Ther Drug Monit. 2019;41:371–5.

Jacobs CL, Gross CR, Messersmith EE, Hong BA, Gillespie BW, Hill-Callahan P, et al. Emotional and financial experiences of kidney donors over the past 50 Years: The RELIVE study. Clin J Am Soc Nephrol. 2015;10:2221–31.

Jeng LB, Lee SG, Soin AS, Lee WC, Suh KS, Joo DJ, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant. 2017; [Epub ahead of print].

Jiang AT, Rowe N, Sener A, Luke P. Simultaneous pancreas-kidney transplantation: The role in the treatment of type 1 diabetes and end-stage renal disease. Can Urol Assoc J. 2014;8:135–8.

Journalist workshop on organ donation and transplantation. Recent facts & figures. November 2014. Available from: http://ec.europa.eu/health/blood_tissues_organs/docs/ev_20141126_factsfigures_en.pdf (accessed June 2017).

Kandaswamy R, Stock PG, Gustafson SK, Skeans MA, Curry MA, Prentice MA, et al. OPTN/SRTR 2015 Annual Data Report: Pancreas. Am J Transplant. 2017;17 Suppl 1:117–173.

Karam VH, Gasquet I, Delvart V, Hiesse C, Dorent R, Danet C, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation. 2003;76:1699–704.

Karthikeyan V, Karpinski J, Nair RC, Knoll G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant. 2004;4:262–9.

Karuthu S, Blumberg EA. Common infections in kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7:2058–70.

Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. Kidney Int. 2010;77:299–311.

Kaufman DB, Odorico JS, Sollinger HW. Chapter 60. Pancreas Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 674–81. 2014; Wiley Online Library.

Keating GM, Lyseng-Williamson KA. Everolimus: a guide to its use in liver transplantation. BioDrugs. 2013;27:407–11.

Kelsh SE, Girgis R, Dickinson M, McDermott JK. Everolimus use for intolerance or failure of baseline immunosuppression in adult heart and lung transplantation. Ann Transplant. 2018 Oct 23;23:744–50.

Kemter E, Wolf E. Pigs pave a way to de novo formation of functional human kidneys. Proc Natl Acad Sci USA. 2015;112:12905–6.

Kern B, Sucher R. Clinical immunosuppression in solid organ and composite tissue allotransplantation. In: Immunosuppression – Role in Health and Diseases. Kapur S, Portela MB (eds). InTech. 2012. Available from: http://www.intechopen.com/books/immunosuppression-role-in-health-and-diseases (accessed June 2017).

Khaja MS, Matsumoto AH, Saad WE. Complications of transplantation. Part 1: renal transplants. Cardiovasc Intervent Radiol. 2014;37:1137–48.

Khalifian S, Grahammer J, Lee WPA, Brandacher G. Stem Cell-based Tolerance Induction in Transplantation. J Stem Cell Res Ther. 2013;S6:003.

Khan A, Nasr P, El-Charabaty E, El-Sayegh S. An insight into the immunologic events and risk assessment in renal transplantation. J Clin Med Res. 2016;8:367–72.

Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9:S1–155.

Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, et al. OPTN/SRTR 2015 Annual Data Report: Liver. Am J Transplant. 2017;17 Suppl 1:174–251.

Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf. 2015;14(7):1055–70.

Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ. 2014;349:g6679.

Kong Y, Wang D, Shang Y, Liang W, Ling X, Guo Z, et al. Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PLoS One. 2011;6:e24387.

Koo TY, Yang J. Current progress in ABO-incompatible kidney transplantation. Kidney Res Clin Pract. 2015;34:170–9.

Koomalsingh K, Kobashigawa JA. The future of cardiac transplantation. Ann Cardiothorac Surg. 2018;7(1):135–42.

Kousoulas L, Neipp M, Barg-Hock H, Jackobs S, Strassburg CP, Klempnauer J, et al. Health-related quality of life in adult transplant recipients more than 15 years after orthotopic liver transplantation. Transpl Int. 2008; 21:1052–8.

Kugler C, Gottlieb J, Warnecke G, Schwarz A, Weissenborn K, Barg-Hock H, et al. Health-related quality of life after solid organ transplantation: a prospective, multiorgan cohort study. Transplantation. 2013;96:316–23.

Kwan JM, Hajjiri Z, Metwally A, Finn PW, Perkins DL. Effect of the Obesity Epidemic on Kidney Transplantation: Obesity Is Independent of Diabetes as a Risk Factor for Adverse Renal Transplant Outcomes. PLoS One. 2016;11:e0165712.

Kymionis GD, Mikropoulos DG, Portaliou DM, Boboridis KG, Voudouragkaki IC, Dragoumis ND, et al. New perspectives on lamellar keratoplasty. Adv Ther. 2014;31:494–511.

Lafranca JA, van Bruggen M, Kimenai HJ, Tran TC, Terkivatan T, Betjes MG, et al. Vascular Multiplicity Should Not Be a Contra-Indication for Live Kidney Donation and Transplantation. PLoS One. 2016;11:e0153460.

Langer RM, Hené R, Vitko S, Christiaans M, Tedesco-Silva H Jr, Ciechanowski K, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int. 2012;25:592–602.

Lao OB, Healey PJ, Perkins JD, Horslen S, Reyes JD, Goldin AB. Outcomes in children after intestinal transplant. Pediatrics. 2010;125:e550–8.

Lee S-G, Moon D-B, Namgoong J-M. Chapter 57. Living Donor Liver Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 639–56. 2014; Wiley Online Library.

Létourneau S, Krieg C, Pantaleo G, Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol. 2009;123:758–62.

Liang L, Sheha H, Li J, Tseng SC. Limbal stem cell transplantation: new progresses and challenges. Eye (Lond). 2009;23:1946–53.

Liu J, Liu D, Li J, Zhu L, Zhang C, Lei K, et al. Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2017;12:e0170246.

Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19:3–26.

Magliocca JF, Hanish SI, Page EK, Knechtle SJ. Chapter 56. Liver Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 631–8. 2014; Wiley Online Library.

Magott-Procelewska M, Madziarska K, Boratynska M, Chudoba P, Lepiesza A, Mazanowska O. Kidney transplantation From Old Deceased Donors: Impact of Uric Acid Level-A Quarter-Century of Experience in One Transplant Center. Transplant Proc. 2018;50:1701–4.

Manara AR, Murphy PG, O’Callaghan G. Donation after circulatory death. Br J Anaesth 2012;108:i108–21.

Manas D, Burnapp L, Andrews PA. Summary of the British Transplantation Society UK Guidelines for living donor liver transplantation. Transplantation. 2016;100:1184–90.

Manitpisitkul W, Lee S, Cooper M. Mycophenolic acid agents: is enteric coating the answer? Transpl Res Risk Management. 2011;3:45–53.

Martin JE, Cavanaugh TM, Trumbull L, Bass M, Weber F Jr, Aranda-Michel J, et al. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients. Clin Transplant. 2008;22:113–9.

Martin P, DiMartini A, Feng S, Brown R Jr, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–65.

Martins AM, Vunjak-Novakovic G, Reis RL. The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine. Stem Cell Rev. 2014;10:177–90.

Masson P, Henderson L, Chapman JR, Craig JC, Webster AC. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev. 2014;11:CD010699.

Mastoridis S, Martínez-Llordella M, Sanchez-Fueyo A. Biomarkers and immunopathology of tolerance. Curr Opin Organ Transplant. 2016;21:81–7.

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334:693–9.

McCracken KW, Catá EM, Crawford CM, Sinagoga KL, Schumacher M, Rockich BE, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids. Nature. 2014;516:400–4.

Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016;35:1–23.

Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates--2006. J Heart Lung Transplant 2006;25:1024–42.

Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant. 2005;5:2273–80.

Meier-Kriesche HU, Steffen BJ, Chu AH, Loveland JJ, Gordon RD, Morris JA, et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant. 2004;4:2058–66.

Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009;27:2278–87.

Messersmith EE, Gross CR, Beil CA, Gillespie BW, Jacobs C, Taler SJ, et al. Satisfaction with life among living kidney donors: A RELIVE study of long term donor outcomes. Transplantation. 2014;98:1294–300.

Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014;44:1479–503.

Middleton SJ, Pither C, Gao R, Duncan S, Green J, Sharkey L, et al. Adult small intestinal and multivisceral transplantation: lessons through the "retrospecto-scope" at a single UK centre from 1991 to 2013. Transplant Proc. 2014;46:2114–8.

Milliman. 2014 U.S. organ and tissue transplant cost estimates and discussion. December 2014; http://www.milliman.com/uploadedFiles/insight/Research/health-rr/1938HDP_20141230.pdf (accessed April 2018).

Mirzakhani M, Mohammadnia-Afrouzi M, Shahbazi M, Mirhosseini SA, Hosseini HM, Amani J. The exosome as a novel predictive/diagnostic biomarker of rejection in the field of transplantation. Clin Immunol. 2019;203:134–41.

Mitta S, Gough SC. Pancreas transplantation a treatment option for people with diabetes. Diabet. Med. 2014;31:512–21.

Mohty M, Bacigalupo A, Saliba F, Zuckermann A, Morelon E, Lebranchu Y. New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs. 2014;74:1605–34.

Montero N, Webster AC, Royuela A, Zamora J, Crespo Barrio M, Pascual J. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients. Cochrane Database Syst Rev. 2014;9:CD007669.

Morales JM, Marcén R, del Castillo D, Andres A, Gonzalez-Molina M, Oppenheimer F, et al. Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study. Nephrol Dial Transplant. 2012;27 Suppl 4:iv39–iv46.

Morard I, Mentha G, Spahr L, Majno P, Hadengue A, Huber O, et al. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant. 2006;20(1):96–101.

Moreno-Borchart A. Building organs piece by piece. Accomplishments and future perspectives in tissue engineering. EMBO Rep. 2004;5:1025–8.

Morrissey PE, Monaco AP. Donation after circulatory death: current practices, ongoing challenges, and potential improvements. Transplantation. 2014;97:258–64.

Muramatsu M, Gonzalez HD, Cacciola R, Aikawa A, Yaqoob MM, Puliatti C. ABO incompatible renal transplants: Good or bad? World J Transplant. 2014;4:18–29.

Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326–33.

Nashan B. mTOR Inhibition and Clinical Transplantation: Liver. Transplantation. 2018;102(2S Suppl 1):S19–26.

NHS Blood and Transplant. Organ Donation and Transplantation: Activity Report 2014-2015. Available from: http://nhsbtmediaservices.blob.core.windows.net/organ-donation-assets/pdfs/activity_report_2014_15.pdf (accessed June 2017).

NHS England. Renal Transplantation. 2013. Available from: https://www.england.nhs.uk/wp-content/uploads/2014/04/a07-renal-transpl-ad-0414.pdf. (accessed June 2017).

Nashan B. mTOR inhibition and clinical transplantation: liver. Transplantation. 2018;102(2S Suppl 1):S19–S26.

Nashan B, Sommerer C, Suwelack B, Dragun D, Hauser I, Witzke O, et al. The Athena study: 12 months safety and efficacy data for everolimus combined with tacrolimus or cyclosporine compared to a standard tacrolimus-mycophenolate regimen in de novo kidney transplant patients. Transplantation 2018;102:pS279.

National Institute for Health and Care Excellence (NICE). Immunosuppressive therapy for renal transplantation in adults. NICE technology appraisal guidance [TA85]. September 2004. Available from: https://www.nice.org.uk/guidance/ta85 (accessed June 2017).

National Institute for Health and Care Excellence (NICE). Immunosuppressive therapy for renal transplantation in children and adolescents. NICE technology appraisal guidance [TA99]. April 2006. Available from: https://www.nice.org.uk/guidance/ta99 (accessed June 2017).

National Institute for Health and Care Excellence (NICE). Living-donor lung transplantation for end-stage lung disease. NICE interventional procedure guidance [IPG170]. May 2006. Available from: https://www.nice.org.uk/guidance/ipg170 (accessed June 2017).

National Institute for Health and Care Excellence (NICE). Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. NICE interventional procedure guidance [IPG257]. April 2008. Available from: https://www.nice.org.uk/guidance/ipg257 (accessed June 2017).

National Institute for Health and Care Excellence (NICE). Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. NICE interventional procedure guidance [IPG274]. September 2008. Available from: https://www.nice.org.uk/guidance/ipg274 (accessed June 2017).

National Institute for Health and Care Excellence (NICE). Corneal endothelial transplantation. NICE interventional procedure guidance [IPG304]. June 2009. Available from: https://www.nice.org.uk/guidance/ipg304 (accessed June 2017).

National Institute for Health and Care Excellence (NICE). Everolimus for preventing organ rejection in liver transplantation. NICE technology appraisal guidance [TA348]. July 2015. Available from: https://www.nice.org.uk/guidance/ta348 (accessed June 2017).

National Institute for Health and Care Excellence (NICE). Living-donor liver transplantation. NICE interventional procedure guidance [IPG535]. November 2015. Available from: https://www.nice.org.uk/guidance/ipg535 (accessed June 2017).

National Kidney Federation. Transplantation Cost Effectiveness. February 2010. Available from: http://www.kidney.org.uk/archives/news-archive-2/campaigns-transplantation-trans-cost-effect/ (accessed June 2017).

Nett PC, Heisey DM, Fernandez LA, Sollinger HW, Pirsch JD. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation. 2004;78:1036–41.

Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: The ‘ReSpECT’ Study. Am J Transplant. 2009;9: 327–36.

Nourbala MH, Hollisaaz MT, Nasiri M, Bahaeloo-Horeh S, Najafi M, Araghizadeh H, et al. Pain affects health-related quality of life in kidney transplant recipients. Transplant Proc. 2007;39:1126–9.

O'Connell PJ, Zhang W, Menon MC, Yi Z, Schröppel B, Gallon L, et al. Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study. Lancet. 2016;388:983–93.

Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–40.

Ojo AO. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol. 2007;27:498–507.

O’Leary JG, Samaniego M, Barrio MC, et al. The influene of immunosuppressive agents on the risk of de novo donor-specific HLA-antibody production in solid organ transplant recipients. Transplantation. 2016;100:39-53.

Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006;25:745–55.

Orens JB, Garrity ER Jr. General overview of lung transplantation and review of organ allocation. Proc Am Thorac Soc. 2009;6:13–9.

Organ Donation Taskforce. The Organ Donation Taskforce Implementation Programme’s Final Report, 2011. 2011. Available from: https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/4249/theorgandonationtaskforcimplementationprogrammesfinalreport2011.pdf (accessed June 2017).

Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29(7):1979–91.

Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant. 2012;27:825–32.

Pascual J, Srinivas TR, Chadban S, Citterio F, Oppenheimer F, Tedesco H, et al. TRANS FORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. Open Access Journal of Clinical Trials. 2014;6:45–54.

Pascual J, Zuckermann A, Djamali A, Hertig A, Naesens M. Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation - A review. Transplant Rev (Orlando). 2016;30:85–91.

Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant. 2015;50:476–82.

Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51:786–92.

Penninga L, Møller CH, Gustafsson F, Gluud C, Steinbrüchel DA. Immunosuppressive T-cell antibody induction for heart transplant recipients. Cochrane Database Syst Rev. 2013a;12:CD008842.

Penninga L, Møller CH, Penninga EI, Iversen M, Gluud C, Steinbrüchel DA. Antibody induction therapy for lung transplant recipients. Cochrane Database Syst Rev. 2013b;11:CD008927.

Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database Syst Rev. 2014;6:CD010253.

Perbos E, Juinier E, Guidicelli G, et al. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant reecipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors. Clin Transplant. 2014;28: 1054–60.

Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus ciclosporin in recipients of extended criteria donor kidneys. Am J Transplant. 2012;12:630–9.

Pinson CW, Feurer ID, Payne JL, Wise PE, Shockley S, Speroff T. Health-related quality of life after different types of solid organ transplantation. Ann Surg. 2000 232:597–607.

Ponziani FR, Mangiola F, Binda C, Zocco MA, Siciliano M, Grieco A, et al. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol. 2017;9:352–67.

Proneth A, Schnitzbauer AA, Schenker P, Wunsch A, Rauchfuss F, Arbogast H et al. Extended pancreas donor program-The EXPAND Study: a prospective multicenter trial testing the use of pancreas donors older than 50 Years. Transplantation. 2018;102:1330–7.

Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, et al. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid. Transpl Infect Dis 2016;18:79–88.

Randleman JB, Song CD, Palay DA. Indications for and outcomes of penetrating keratoplasty performed by resident surgeons. Am J Ophthalmol. 2003;136:68–75.

Ravichandran R, Bansai S, Rahman M, Sharma M, Liu W, Bharat A et al. The role of donor-derived exosomes in lung allograft rejection. Hum Immunol. 2019 Mar 18 (epub ahead of print).

Redfield RR, Scalea JR, Odorico JS. Simultaneous pancreas and kidney transplantation: current trends and future directions. Curr Opin Organ Transplant. 2015;20:94–102.

Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. A Definition of Irreversible Coma. JAMA. 1968;205:337–340.

Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013;13:2875–83.

Rummo OO, Carmellini M, Rostaing L, Oberbauer R, Christiaans MH, Mousson C, et al. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. Transpl Int. 2017;30:83–95.

Saber-Moghaddam N, Nomani H, Sahebkar A, Johnston TP, Mohammadpour AH. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation. Int Immunopharmacol. 2019 Apr;69:150–8.

Sáez-Giménez B, Berastegui C, Loor K, López-Meseguer M, Monforte V, Bravo C, et al. Deep vein thrombosis and pulmonary embolism after solid organ transplantation: an unresolved problem. Transplant Rev (Orlando). 2015;29:85–92.

Sageshima J, Ciancio G, Chen L, Burke GW. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics. 2009;3:319–36.

Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013;13:1734–45.

Saliba F, Duvoux C, Gugenheim J, Kamar N, Dharancy S, Salamé E, et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: A multicenter, randomized trial. Am J Transplant. 2017;17(7):1843–52.

Saliba F, Fischer L, de Simone P, Bernhardt P, Bader G, Fung J. Association between renal dysfunction and major adverse cardiac events after liver transplantation: evidence from an international randomized trial of everolimus-based immunosuppression. Ann Transplant. 2018;23:751–7.

Salis P, Caccamo C, Verzaro R, Gruttadauria S, Artero M. The role of basiliximab in the evolving renal transplantation immunosuppression protocol. Biologics. 2008;2:175–88.

Salvadori M, Bertoni E. Long-term outcome of everolimus treatment in transplant patients. Transpl Res Risk Management. 2011:3 77–90.

Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231–6.

Salvadori M, Rosso G, Bertoni E. Update on ischemia-reperfusion injury in kidney transplantation: Pathogenesis and treatment. World J Transplant. 2015;5:52–67.

Sayegh MH. Looking into the crystal ball: kidney transplantation in 2025. Nat Clin Pract Nephrol. 2009;5:117.

Schnitzler MA, Skeans MA, Axelrod DA, Lentine KL, Randall HB, Snyder JJ, et al. OPTN/SRTR 2015 Annual Data Report: Economics. Am J Transplant. 2017;17 Suppl 1:425–502.

Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA. 2010;303:959–66.

Shapiro AMJ, Ricordi C. Chapter 61. Islet Cell Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 682–90. 2014; Wiley Online Library.

Sharma M, Ravichandran R, Bansal S, Bremner RM, Smith MA, Mohanakumar T. Tissue-associated self-antigens containing exosomes: Role in allograft rejection. Hum Immunol. 2018;79:653–8.

Shrestha B, Haylor J, Raftery A. Historical perspectives in kidney transplantation: an updated review. Prog Transplant. 2015;25(1):64–9.

Singh D, Taylor DO. Advances in the understanding and management of heart transplantation. F1000Prime Rep. 2015;7:52.

Singh S, Watt KD. Long-term medical management of the liver transplant recipient: what the primary care physician needs to know. Mayo Clin Proc. 2012;87:779–90.

Smith JM, Skeans MA, Horslen SP, Edwards EB, Harper AM, Snyder JJ, et al. OPTN/SRTR 2015 Annual Data Report: Intestine. Am J Transplant. 2017;17 Suppl 1:252–285.

Sommerer C, Duerr M, Witzke O, Lehner F, Arns W, Kliem V, et al. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. Am J Transplant. 2018. [Epub ahead of print].

Squires RH, Ng V, Romero R, Ekong U, Hardikar W, Emre S, et al. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Hepatology. 2014;60:362–98. Available at: https://www.aasld.org/sites/default/files/2019-06/EvaluationPediatricLT2014.pdf (accessed July 2019).

Steering Committee of the Istanbul Summit. Organ trafficking and transplant tourism and commercialism: the Declaration of Istanbul. Lancet. 2008;372:5–6.

Stegall MD, Cornell LD, Park WD, Smith BH, Cosio FG. Renal allograft histology at 10 years after transplantation in the tacrolimus era: evidence of pervasive chronic injury. Am J Transplant. 2018;18: 180–8.

Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM. The outcomes of adult liver transplants in the United States from 1987 to 2013. Liver Int. 2015;35(8):2036–41.

Sterneck M, Kaiser GM,, Heyne N, Richter N, Rauchfuss F, Pascher A, et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant. 2016;30:741–8.

Tabar V, Studer L. Pluripotent stem cells in regenerative medicine: challenges and recent progress. Nat Rev Genet. 2014;15:82–92.

Taguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H, et al. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell. 2014;14:53–67.

Takahashi K, Uchida K, Yoshimura N, Takahara S, Teraoka S, Teshima R, et al. Efficacy and safety of concentration-controlled everolimus with reduced-dose ciclosporin in Japanese de novo renal transplant patients: 12-month results. Transplant Res 2013;2:14.

Tan DT, Dart JK, Holland EJ, Kinoshita S. Corneal transplantation. Lancet. 2012;379:1749–61.

Teperman L, Moonka D, Sebastian A, Sher L, Marotta P, Marsh C, et al. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl. 2013;19:675–89.

Thimonier E, Guillaud O, Walter T, Decullier E, Vallin M, Boillot O, et al. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease. Clin Transplant. 2014;28:1339–48.

Thomusch O, Wiesener M, Opgenoorth M, Pascher A, Woitas RP, Witzke O, et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Lancet. 2016;388:3006–16.

Torres-Gutiérrez M. Psycho-social evaluation of a living kidney donor. Rev Colomb Psiquiatr. 2018;47:252–7.

Tsai KF, Li LC, Hsu CN, Lin CC, Lin YH, Cheng YF, et al. Effects of conversion from calcineurin inhibitors to sirolimus or everolimus on renal function and possible mechanisms in liver transplant recipients. J Clin Pharmacol. 2018. [Epub ahead of print].

Tso PL, Pearson TC. Chapter 55. Kidney Transplantation Procedure and Surgical Technique. In: Textbook of Organ Transplantation. Kirk AD, Knechtle SJ, Larsen CP, Madsen JC, Thomas C. Pearson TC, et al. (eds.) pp 617–30. 2014; Wiley Online Library.

Tedesco Silva H Jr, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10:1401–13.

Tonsho M, Michel S, Ahmed Z, Alessandrini A, Madsen JC. Heart transplantation: challenges facing the field. Cold Spring Harb Perspect Med. 2014;4. pii:a015636.

Uchida J, Tomoaki I, Nakatani T. Introduction of everolimus in kidney transplant recipients at a late posttransplant stage. World J Transplant. 2018a;8:150–5.

Uchida J, Nishide S, Kabei K, Shimada H, Kosoku A, Iwai T, et al. Effect of age on conversion to everolimus with calcineurin inhibitor minimization at a late post-transplant stage. Urol J. 2018b;15:266–71.

United Network for Organ Sharing (UNOS). Transplants By Organ Type January 1, 1988 - January 31, 2016. 2016. Available from: https://www.unos.org/data/ (accessed June 2017).

United Network for Organ Sharing (UNOS). Policy brochures. 2015. Available from: https://www.unos.org/policy/policy-brochures/(accessed June 2017).

United States Renal Data System (USRDS). 2015 Annual Data Report. 2015. Available from: https://www.usrds.org/2015/view/ (accessed June 2017).

US Department of Health and Human Services. Organ Procurement and Transplant Network Annual Data Report 2012. Published June 2014. Available from: https://srtr.transplant.hrsa.gov/annual_reports/2012/pdf/2012_SRTR_ADR_updated_full_intro.pdf  accessed March 2018.

Valapour M, Skeans MA, Smith JM, Edwards LB, Cherikh WS, Uccellini K, et al. OPTN/SRTR 2015 Annual Data Report: Lung. Am J Transplant. 2017;17 Suppl 1:357–424.

van Sandwijk MS, de Vries APJ, Bakker S, Ten Berge IJM, Berger SP, Bouatou YR, et al. Early steroid withdrawal compared with standard immunosuppression in kidney transplantation – interim analysis of the Amsterdam-Leiden-Groningen randomised control trial. Transplantation Direct. 2018;4(6):e354.

Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf. 2016;15:303–19.

Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus ciclosporin in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535–46.

Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333–43.

Wagner M, Earley AK, Webster AC, Schmid CH, Balk EM, Uhlig K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2015;12:CD007746.

Watson CL, Mahe MM, Múnera J, Howell JC, Sundaram N, Poling HM, et al. An in vivo model of human small intestine using pluripotent stem cells. Nat Med. 2014;20:1310–4.

Watson CJ, Dark JH. Organ transplantation: historical perspective and current practice. Br J Anaesth. 2012;108 Suppl 1:i29–42.

Wei TY, Chiang YJ, Hsieh CY, Weng LC, Lin SC, Lin MH. Health related quality of life of long-term kidney transplantation recipients. Biomed J. 2013;36:243–51.

Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15.

Weiss DJ. Current status of stem cells and regenerative medicine in lung biology and diseases. Stem Cells. 2014;32:16–25.

Wolf S, Hoffmann VS, Habicht A, Kauke T, Bucher J, Schoenberg M, et al. Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months. PLoS One. 2018;13(4):e0194975.

Xie X, Jiang Y, Lai X, Xiang S, Shou Z, Chen J. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis. BMC Nephrol. 2015;16:91.

Xu DW, Wan P, Xia Q. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria: A review. World J Gastroenterol. 2016;22:3325–34.

Yokote S, Matsunari H, Iwai S, Yamanaka S, Uchikura A, Fujimoto E, et al. Urine excretion strategy for stem cell-generated embryonic kidneys. Proc Natl Acad Sci USA. 2015;112:12980–5.

Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015;34:1264–77.

Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury. JAMA. 2016;315(20):2190–9.

Zavras N, Misiakos E, Konstantinos V, Salakos C. Short-bowel syndrome in children — an update in management strategies. Chapter 8. In: Pediatric Nursing, Psychiatric and Surgical Issues. Ozdemir O .(ed.). 2015; InTech (online), Available from https://www.intechopen.com/books/pediatric-nursing-psychiatric-and-surgical-issues/short-bowel-syndrome-in-children-an-update-in-management-strategies (accessed June 2017).

Zhang X. Direct anti-HCV agents. Acta Pharm Sin B. 2016;6:26–31.

Zhao DQ, Li SW, Sun QQ. Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review. Transplant Proc. 2016;48:3–9.